Please assess the completion status of the following clinical trial:

Trial Title: Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~diagnosis of fibromyalgia made by a practicing physician between the ages of 18-85 existing pain for more than 3 months pain resistant to common analgesics or intolerance to common analgesics Active Duty service members widespread pain in at least 7 of 19 areas; as reported by the patient symptom severity scale score over five including symptoms of fatigue, awaking unrefreshed and brain fog~Exclusion Criteria:~Pregnancy ages under 18 and over 85 years of age Non Active Duty service members Anaphylactic reactions Allergy to latex Drug or alcohol abuse severe depression change in CNS active medications in the preceding 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): 1ml 0.9% of saline once a month in addition to the standard of care practiced at NMCP.
- Erenumab (Type: EXPERIMENTAL): 140mg (1 ml) of Erenumab injected once a month in addition to the standard of care practiced at NMCP.

Based on this trial design, predict the completion outcome and termination type (if applicable).